<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166929</url>
  </required_header>
  <id_info>
    <org_study_id>2588</org_study_id>
    <nct_id>NCT04166929</nct_id>
  </id_info>
  <brief_title>Haploidentical Bone Marrow Transplant With or Without NK Cell Infusion in AML and MDS</brief_title>
  <acronym>Bigeminy</acronym>
  <official_title>Haploidentical Bone Marrow Transplantation With or Without NK Cell Infusion in Refractory/Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome:The BigEMINy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relapse after an allogeneic hematopoietic stem cell transplantation (HSCT) is high in
      patients with advanced AML, in the 50% range. NK cells have been shown to possess significant
      anti-leukemic activity and may be used to reduce the incidence of relapse in patients with
      advanced AML.

      Investigators hypothesize that the administration of a purified boost of NK cells on day +7
      post HSCT, will reduce the incidence of relapse from the current 50% to 25%. In a phase III
      multicenter clinical study, 116 patients will be randomized to receive or not a boost of
      donor NK cells on day +7 post-HSCT. The first 10 patients in the experimental arm will be
      analyzed for toxicity. The stopping rule will be a transplant related mortality of more than
      50% in the first 20 patients who received NK cells.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Anticipated">January 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leukemia relapse</measure>
    <time_frame>1 year after bone marrow transplant</time_frame>
    <description>Cumulative incidence of leukemia relapse.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplasia</condition>
  <arm_group>
    <arm_group_label>Haplo-BMT followed by NK infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Haplo bone marrow transplant is follewd by a haplo-NK cell infusion (target dose â‰¥1*106/kg b.w.) at day 7.
Unstimulated haplo-NK cells are collected through apheresis Mononuclear cells are then subjected to a preliminary negative selection of CD3+ cells and to a subsequent positive selection of CD56+ cells. CD3 negative/CD56 positive cells are infused</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Haplo BMT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm receive standard haplo bone marrow transplant without subsequent NK cell infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haplo BMT with NK cells</intervention_name>
    <description>Patients in this arm receive haplo-BMT followed by one boost of NK cells one/two weeks after the transplant. Lymphocyte are collected by apheresis from the donor one-two weeks after BM harvest. CD3 negative/CD56 positive cells are selected by immunomagnetic columns (other lymphocytes are stored to be used as DLI)</description>
    <arm_group_label>Haplo-BMT followed by NK infusion</arm_group_label>
    <other_name>haplo BMT followed by NK cell infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haplo BMT</intervention_name>
    <description>Patients in this arm receive a standard haplo-BMT. All administerd therapies are the same as in other arm, except for the NK cell boost..</description>
    <arm_group_label>Haplo BMT</arm_group_label>
    <other_name>Standard haplo BMT without subsequent NK cell boost.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of AML or MDS

          -  Patients not in remission at the time of transplant

          -  Age 18-75

          -  ECOG performance status &lt;2

          -  Availability of a family HLA haploidentical donor, eligible to donate both marrow
             cells and unstimulated lymphocytes (1 apheresis procedure at day +7) .

        Exclusion Criteria:

          -  Positive serologic markers for human immunodeficiency virus (HIV)

          -  Acute hepatitis B virus (HBV) or acute hepatitis C virus (HCV) infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Bacigalupo, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Gemelli IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Bacigalupo, Prof</last_name>
    <phone>+390630154180</phone>
    <email>andrea.bacigalupo@unicatt.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luciana Teofili, Dr</last_name>
    <email>luciana.teofili@unicatt.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Bacigalupo, Prof.</last_name>
      <phone>0630154180</phone>
      <email>andrea.bacigalupo@unicatt.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>March 28, 2020</last_update_submitted>
  <last_update_submitted_qc>March 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

